These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 8588437)

  • 1. [Legal liability in clinical trials from the legal-pharmaceutical viewpoint].
    Amon F
    Z Arztl Fortbild (Jena); 1995 Nov; 89(6):638-41. PubMed ID: 8588437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Legal liability in clinical trials from the viewpoint of the clinician].
    Luft FC
    Z Arztl Fortbild (Jena); 1995 Nov; 89(6):646-8; discussion 649-52. PubMed ID: 8588439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The physician and the law. Responsibility after a liability incident--what can, what should be done from the legal viewpoint?].
    Ulsenheimer K; Bock RW
    Chirurg; 1991 Nov; 62(11):suppl 193-6. PubMed ID: 1769247
    [No Abstract]   [Full Text] [Related]  

  • 4. [Medical malpractice from the viewpoint of the insurer].
    Kochs B
    Z Arztl Fortbild (Jena); 1995 Nov; 89(6):575-80. PubMed ID: 8588426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Legal liability in drug trials].
    Frölich JC
    Z Arztl Fortbild (Jena); 1995 Nov; 89(6):641-6. PubMed ID: 8588438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Supreme Court, preemption, and malpractice liability.
    Kesselheim AS; Studdert DM
    N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
    [No Abstract]   [Full Text] [Related]  

  • 7. [Responsibility for patient education in drug therapy from the viewpoint of the pharmaceutical industry].
    Sander A
    Z Arztl Fortbild (Jena); 1994 Dec; 88(12):1061-3. PubMed ID: 7716983
    [No Abstract]   [Full Text] [Related]  

  • 8. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 9. [Medical expert assessment in civil and criminal law from the legal liability viewpoint].
    Kümper HJ
    Z Arztl Fortbild (Jena); 1996 Nov; 90(7):589-90; discussion 591. PubMed ID: 9064928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
    Ochs A
    Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
    [No Abstract]   [Full Text] [Related]  

  • 11. [Perspectives in medical liability].
    Pizarro W C
    Rev Med Chil; 2008 Apr; 136(4):539-43. PubMed ID: 18769798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation with placebo effects.
    Malani A
    Duke Law J; 2008 Dec; 58(3):411-72.. PubMed ID: 19353835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The errors of error testing: potential liability issues for medication error testing of pharmaceutical trademarks under U.S. law.
    Thomas JA
    Food Drug Law J; 2004; 59(2):325-37. PubMed ID: 15298014
    [No Abstract]   [Full Text] [Related]  

  • 14. [Malpractice insurance of the physician].
    Krieger G
    Chirurg; 1991 Feb; 62(2):suppl 29-34. PubMed ID: 2044415
    [No Abstract]   [Full Text] [Related]  

  • 15. [Off-label use of drugs--the legal framework].
    Koyuncu A
    Dtsch Med Wochenschr; 2012 Jul; 137(30):1519-23. PubMed ID: 22869512
    [No Abstract]   [Full Text] [Related]  

  • 16. Disease-branding and drug-mongering: could pharmaceutical industry promotional practices result in tort liability?
    Cetel JS
    Seton Hall Law Rev; 2012; 42(2):643-702. PubMed ID: 22708139
    [No Abstract]   [Full Text] [Related]  

  • 17. [Indemnity legislation: employee's liability was restricted].
    Molkentin T
    Pflege Z; 1999 May; 52(5):340-2. PubMed ID: 10514734
    [No Abstract]   [Full Text] [Related]  

  • 18. [Legal liability of subordinate physicians, legal liability for management responsibility from the jurisprudence viewpoint].
    Weissauer W
    Z Arztl Fortbild (Jena); 1995 Nov; 89(6):613-20. PubMed ID: 8588433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
    Chodock R; Yolkut D; Connolly DR
    Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.